This site, AZILECT.com, is an AZILECT information resource published over the Internet and intended only to provide broad consumer understanding and knowledge of AZILECT. The site was developed specifically for individuals who are U.S. residents. This content has not been approved for non-U.S. residents. The information should not be considered complete and should not be used in place of a visit, call, consultation, or advice of your physician or other healthcare provider. The Web site does not recommend the self-management of health problems. Information obtained through this site is not exhaustive and does not cover all ailments, physical conditions, or their treatment. Should you have any healthcare-related questions, please call or see your physician or other healthcare provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here.

VISITORS TO AZILECT.COM ARE URGED AND ADVISED TO SEEK THE ADVICE OF A PHYSICIAN BEFORE BEGINNING ANY TREATMENT. Such individuals are specifically warned to seek professional medical advice prior to initiating any form of health treatment.


AZL101023711/101193

 

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s Disease (PD) as initial monotherapy and as adjunct therapy to levodopa.

IMPORTANT SAFETY INFORMATION ABOUT AZILECT

Azilect is contraindicated with meperidine; the analgesics tramadol, methadone, and propoxyphene; the antitussive agent dextromethorphan; as well as St. John’s wort and cyclobenzaprine. Azilect is also contraindicated with other MAOIs.

In general, the combination of Azilect and antidepressants should be avoided. Caution should be used when giving Azilect concurrently with CYP1A2 inhibitors such as ciprofloxacin. Patients with moderate to severe hepatic impairment should not take Azilect. The daily dose of Azilect should not exceed 1 mg because of the risks associated with nonselective inhibition of MAO. PD patients are advised to monitor for melanoma frequently and see a dermatologist on a regular basis.

The most common side effects as monotherapy include: flu syndrome, arthralgia, depression, and dyspepsia; and as adjunct to levodopa therapy include: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.

AZL101023762/101241